Sie sind auf Seite 1von 18

564673

review-article2014

TAG0010.1177/1756283X14564673Therapeutic Advances in GastroenterologyK. Lenz et al.

Therapeutic Advances in Gastroenterology

Review

Treatment and management of ascites and


hepatorenal syndrome: an update
Kurt Lenz, Robert Buder, Lisbeth Kapun and Martin Voglmayr

Ther Adv Gastroenterol


2015, Vol. 8(2) 83100
DOI: 10.1177/
1756283X14564673
The Author(s), 2014.
Reprints and permissions:
http://www.sagepub.co.uk/
journalsPermissions.nav

Abstract: Ascites and renal dysfunction are frequent complications experienced by patients
with cirrhosis of the liver. Ascites is the pathologic accumulation of fluid in the peritoneal
cavity, and is one of the cardinal signs of portal hypertension. The diagnostic evaluation of
ascites involves assessment of its granulocyte count and protein concentration to exclude
complications such as infection or malignoma and to allow risk stratification for the
development of spontaneous peritonitis. Although sodium restriction and diuretics remain the
cornerstone of the management of ascites, many patients require additional therapy when
they become refractory to this treatment. In this situation, the treatment of choice is repeated
large-volume paracentesis. Alteration in splanchnic hemodynamics is one of the most
important changes underlying the development of ascites. Further splanchnic dilation leads to
changes in systemic hemodynamics, activating vasopressor agents and leading to decreased
renal perfusion. Small alterations in renal function influence the prognosis, which depends
on the cause of renal failure. Prerenal failure is evident in about 70% of patients, whereas
in about 30% of patients the cause is hepatorenal syndrome (HRS), which is associated with
a worse prognosis. Therefore, effective therapy is of great clinical importance. Recent data
indicate that use of the new definition of acute kidney injury facilitates the identification and
treatment of patients with renal insufficiency more rapidly than use of the current criteria
for HRS. In this review article, we evaluate approaches to the management of patients with
ascites and HRS.

Keywords: acute kidney injury, ascites, diuretic therapy, hepatorenal syndrome

Introduction
Ascites is the most common complication of cirrhosis with attendant portal hypertension [Moore
and Aithal, 2006]. The production of ascites is
related to inadequate renal sodium excretion,
which generates a positive sodium balance. A typical finding in patients with cirrhosis and portal
decompensation is arterial splanchnic vasodilation, which results in increased mesenteric blood
flow. Arterial splanchnic vasodilation causes a
decrease in effective blood volume, activating
baro and volume receptors, the sympathetic nervous system, and the reninangiotensinaldosterone system (RAAS) and triggering the nonosmotic
release of vasopressin. Increased renal sympathetic nerve activity leads to increased tubular
sodium retention and a positive sodium balance.
Renal sympathetic nerve activity is further
enhanced by activation of the hepatorenal reflex

secondary to increased sinusoidal pressure and/or


a decrease in sinusoidal blood flow [Ming et al.
2002]. Increased vasodilation in the splanchnic
area is counteracted by an increase in total blood
flow, maintaining normal blood pressure and an
adequate blood flow to all organs. However, further splanchnic vasodilation increases the activation of vasoconstrictor systems and leads to
central underfilling, which cannot be sufficiently
counteracted by increasing cardiac output. This
causes decreased blood flow to the kidney and
prerenal failure, termed hepatorenal syndrome
(HRS) in these patients.

Correspondence to:
Kurt Lenz, MD
Department of Internal
and Intensive Care
Medicine, Konventhospital
Barmherzige Brder
Linz, Seilersttte 2, Linz,
A-4020, Austria
kurt.lenz@meduniwien.
ac.at
Robert Buder, MD
Martin Voglmayr, MD
Department of Internal
and Intensive Care
Medicine, Konventhospital
Barmherzige Brder Linz,
Austria
Lisbeth Kapun, MD
HFR Meyriez-Murten,
Murten, Switzerland

Ascites
Ascites is a major complication of cirrhosis of the
liver, and is mainly due to portal hypertension.
Within 10 years of the diagnosis of cirrhosis, over

http://tag.sagepub.com 83

Therapeutic Advances in Gastroenterology 8(2)


50% of patients develop ascites [Becker, 2011].
The development of ascites is associated with a
poor prognosis and a mortality rate of 20% per
year [DAmico et al. 2006]. Therefore, patients
with ascites should be considered for liver transplantation, preferably before the development of
renal dysfunction.
Because 15% of patients with cirrhosis of the liver
develop ascites of nonhepatic origin, the cause of
new-onset ascites must be evaluated in all patients
by abdominal paracentesis. The analysis of ascitic
fluid should include assessment of neutrophil count
and total protein concentration. Inoculation of
ascites into blood culture bottles should be performed at the bedside if infection of the ascitic fluid
is suspected. A diagnosis of spontaneous bacterial
peritonitis (SBP) is made in the presence of an elevated absolute polymorphonuclear leukocyte count
(i.e. >250 cells/mm3) in the ascitic fluid without evidence of a surgically treatable intra-abdominal
source of infection [Becker, 2011]. Determination
of the ascitic protein concentration is necessary to
identify patients at increased risk of the development of SBP: a protein concentration of <1.5 g/dl is
a risk factor for development of the condition
[Moore and Aithal, 2006]. In patients in whom a
cause of ascites other than cirrhosis of the liver is
suspected, determination of the serumascites albumin gradient (SAAG) is useful. The SAAG is
1.1 g/dl in ascites due to portal hypertension, with
an accuracy of 97% [Gines et al. 2010]. If ascites
associated with malignancy is suspected, positive
results of cytologic analyses of ascitic fluid can be
obtained in patients with peritoneal carcinomatosis,
but not in those with liver metastasis or hepatoma
[Runyon et al. 1988]. Paracentesis is considered a
safe procedure even in patients with an abnormal
prothrombin time, with an overall complication rate
not exceeding 1%. More serious complications,
such as bowel perforation or bleeding into the
abdominal cavity, occur in fewer than 1 in 1000
paracenteses. Data supporting cutoff values for
coagulation parameters are unavailable; routine
prophylactic use of fresh-frozen plasma or platelets
before paracentesis is therefore not recommended,
although if thrombocytopenia is severe (platelet
count 40,000/l), most clinicians would administer pooled platelets to reduce the risk of bleeding
[Gines etal. 2010, Moore and Aithal, 2006].
Treatment
Decompensated cirrhosis due to chronic viral or
autoimmune hepatitis often shows marked

improvement in response to antiviral or immunosuppressive treatments, respectively. In most


patients with alcoholic liver disease, abstinence
from alcohol results in improvements in liver
function and ascites [Becker, 2011]. There are no
defined criteria for when the treatment of ascites
should be initiated. Patients with clinically unapparent ascites usually do not require specific therapy, but it is recommended that patients with
clinically evident and symptomatic ascites
undergo treatment [Moore etal. 2003].
Patients with ascites have a positive sodium balance, i.e. sodium excretion is low relative to
sodium intake. Hence, the mainstay of therapy
for ascites is sodium restriction and diuretic therapy (Table 1). Sodium intake should be restricted
to 56 g/day (83100 mmol/day of NaCl). More
stringent restriction is not recommended,
because it may worsen the malnutrition often
present in patients with cirrhosis [Soulsby etal.
1997]. Given that the spontaneous resolution of
ascites is obtained by reducing dietary sodium
content in only 1020% of patients, a negative
sodium balance cannot be achieved without the
use of diuretics in most patients with cirrhosis
and ascites. Activation of the RAAS in patients
with cirrhosis of the liver causes hyperaldosteronism and increased reabsorption of sodium
throughout the distal tubule [Bernardi et al.
1985]. Therefore, aldosterone antagonists, such
as spironolactone, or its active metabolite, potassium canrenoate [Perez-Ayuso etal. 1982], represent first-line diuretics in the treatment of
ascites in patients with cirrhosis. The initial dose
is 100200 mg/dl. Monotherapy with a loop diuretic such as furosemide is less effective than use
of spironolactone, and is not recommended (86)
Perez-Ayuso etal. 1982. Two different schedules
are used in clinical practice. The first (sequential
diuretic treatment) consists of the administration of increasing doses of spironolactone. If the
response to 200 mg spironolactone is insufficient
within the first 2 weeks, furosemide is added at
an initial dose of 2040 mg/day. If necessary, the
dose of spironolactone can be increased stepwise
to a maximum of 400 mg/day, and the dose of
furosemide can be increased to a maximum of
160 mg/day. The second schedule (combined
diuretic treatment) involves the simultaneous
administration of an aldosterone antagonist and
a loop diuretic from the beginning of treatment,
and the dose of both diuretics can be increased if
no response is achieved. An established scheme
for initial combined therapy is 100 mg

84 http://tag.sagepub.com

K Lenz, R Buder et al.


Table 1. Treatment of ascites.
Clinical findings

Treatment

Ascites clinically not detectable


Clinically evident ascites

No treatment
Combined treatment with:
Dietary salt restriction
Aldosterone antagonists (starting dose of
spironolactone 50100 mg tapering to a
maximum of 400 mg until ascites is resolved)
Loop diuretics (starting dose of furosemide
40 mg tapering to a maximum of 160 mg until
ascites is resolved or hyponatremia occurs)
Reduce the diuretic dose by half every week under
weight control

Ascites completely mobilized by diuretic treatment

spironolactone and 40 mg furosemide per day,


administered in the morning. If this dosage is
insufficient, a stepwise increase, keeping the
spironolactone:furosemide ratio constant (e.g.
200 mg spironolactone:80 mg furosemide), is
possible. In a study by Angeli and colleagues
[Angeli etal. 2010], adverse effects (38% versus
20%; p<0.05), in particular hyperkalemia (18%
versus 4%; p < 0.05), were more common in
patients who received sequential therapy, and the
percentage of patients whose ascites resolved
without changing the effective diuretic step was
higher with combined treatment (56% versus
76%; p < 0.05). The combination of sodium
restriction, spironolactone, and furosemide is
sufficient therapy for ascites in 90% of patients
with cirrhosis of the liver [Becker, 2011].
To avoid hypovolemia, daily weight loss in patients
with ascites should not exceed 1000 g in the presence of peripheral edema or 500 g in the absence
of peripheral edema [Pockros and Reynolds,
1986]. The diuretic effect is sufficient when only
small amounts of ascitic fluid remain and peripheral edema has disappeared completely.
Complications of diuretic therapy include hepatic
encephalopathy, renal failure, gynecomastia, electrolyte disturbances such as hyponatremia and
hypokalemia or hyperkalemia, and muscle cramps
[Santos etal. 2003]. To minimize these complications, it is advisable to reduce the dosage of diuretic drugs after the mobilization of ascites.
Complications of diuretic therapy are most frequent in the first few weeks of therapy. Amiloride
is an alternative to spironolactone in patients with
painful gynecomastia. It is administered at a dose
of 1040 mg/day, but it is less effective than potassium canrenoate [Angeli et al. 1994]. Notably,
hyponatremia, which is caused by impaired free

water excretion, itself reduces the effect of loop


diuretics.
The level of hyponatremia at which diuretic
treatment should be stopped is contentious. It is
generally agreed that diuretics should be paused
when serum sodium is <120125 mmol/l
[Runyon, 2012]. Low serum sodium concentration is an independent predictor of mortality in
patients with cirrhosis. The prevalence of low
serum sodium concentration, as defined by
serum sodium concentrations of <135 mmol/l,
<130 mmol/l, <125 mmol/l, and <120 mmol/l,
was found to be 49.4%, 21.6%, 5.7%, and 1.2%,
respectively, in a large multicenter study involving 994 patients with cirrhosis [Angeli et al.
2006]. Given that total body sodium is usually
not decreased in patients with ascites and
hyponatremia (dilution hyponatremia = hypervolemic hyponatremia), fluid restriction is recommended. Albumin infusion can be considered
a treatment for hyponatremia in cirrhosis. The
available data are limited and derive from a
small number of patients with a short follow-up,
but they suggest a benefit of albumin administration that warrants further exploration in
larger randomized trials. A randomized pilot
study of 24 patients admitted with serum
sodium levels of <130 mmol/l found that the
administration of albumin significantly improved
serum sodium levels compared with matched
controls treated with fluid restriction, generating a mean increase of 9 mmol/l. There was also
a significant increase, compared with controls,
in free water clearance and a decrease in serum
vasopressin levels in patients treated with albumin [Jalan etal. 2007]. This suggests that albumin contributes to the mitigation of circulatory
dysfunction and decreases the nonosmotic

http://tag.sagepub.com 85

Therapeutic Advances in Gastroenterology 8(2)


release of arginine vasopressin [Gianotti and
Cardenas, 2014; Umgelter et al. 2012].
Hypervolemic hyponatremia should be differentiated from hypovolemic hyponatremia, a less
common condition in cirrhosis in which hypovolemia results from marked and prolonged loss
of sodium. In this condition, if the hyponatremia
is symptomatic, slow correction is indicated.
The desirable rate of sodium increase is considered to be 68 mEq/l in 24 hours, 1214 mEq/l
in 48 hours, and 1416 mEq/l in 72 hours. A
more rapid correction of serum sodium is not
recommended, because of the risk of severe
complications, especially pontine myelinolysis
[Tzamaloukas etal. 2013].
In recent years, new drugs known as vaptans,
which antagonize the vasopressin V2 receptor
[Decaux and Vassart, 2008], have been used to
treat hyponatremia caused by cardiac failure,
syndrome of inappropriate antidiuretic hormone secretion (SIADH), and cirrhosis. In randomized studies, administration of tolvaptan
induced a marked increase in urine flow and
serum sodium concentration in patients with
mild hyponatremia. However, in those with
marked hyponatremia and renal failure, there
was only a trend toward improvement of serum
sodium concentration, and the effect only
occurred during the administration of tolvaptan. One week after vaptan cessation, hyponatremia recurred [Cardenas et al. 2012].
Tolvaptan was associated with an as yet unexplained higher incidence of gastrointestinal
bleeding when compared with the administration of a placebo. Therefore, the use of tolvaptan
warrants further long-term studies to evaluate
its safety and efficacy.
Therapy for refractory and recurrent ascites
Refractory ascites is defined as ascites that does
not respond to sodium restriction and high-dose
diuretic treatment (400 mg/day spironolactone
and 160 mg/day furosemide) or that recurs rapidly after therapeutic paracentesis [Gines et al.
2010]. About 510% of patients with cirrhosis
and ascites are considered to have refractory
ascites (63) (Krag etal. 2007). The median survival of patients with ascites refractory to medical
treatment is approximately 6 months. Recurrent
ascites is defined as frequent admission to the
hospital (more than three admissions per year)
because of the reaccumulation of ascites [Arroyo,
2013].

Large-volume paracentesis (LVP) is the first-line


therapy in patients with refractory ascites. In
patients with recurrent ascites, the addition of
vasopressors (with or without albumin) or albumin alone can be tried, before invasive procedures
such as paracentesis are attempted (Table 2). In
patients with cirrhosis and activation of the sympathetic nervous system, the addition of clonidine
to diuretic therapy induced an earlier diuretic
response associated with reduced diuretic requirements, fewer complications, and a lower incidence
of readmission related to tense ascites [Laenerts
etal. 1997]. Several mechanisms may contribute
to the increased mobilization of ascites associated
with the use of clonidine. Clonidine induced a
reduction in norepinephrine concentration associated with an elevated glomerular filtration rate
in patients with refractory ascites [Laenerts etal.
2006]. By increasing glomerular filtration rate
and decreasing proximal reabsorption of sodium,
clonidine may increase the delivery of sodium to
the distal nephron, where spironolactone, initially
less effective, increases natriuresis by impairing
the distal reabsorption of sodium. In addition,
clonidine decreases the portosystemic gradient,
especially in patients with alcoholic cirrhosis.
Oral administration of midodrine is associated
with a significant improvement in systemic hemodynamics in nonazotemic patients with cirrhosis
and ascites. As a result, renal perfusion and renal
sodium excretion also improve in these patients
[Angeli etal. 1998]. In a randomized controlled
trial, midodrine and a combination of clonidine,
midodrine, and standard diuretic treatment controlled ascites significantly better than standard
diuretic treatment alone over a 1-month period
[Singh etal. 2013]. In a randomized trial involving patients with refractory or recurrent ascites,
oral midodrine at a dose of 7.5 mg three times
daily was shown to increase urine volume, urinary
sodium excretion, mean arterial pressure, and
survival. Therefore, midodrine can used in addition to diuretics to increase blood pressure and
convert refractory ascites to diuretic-sensitive
ascites [Singh etal. 2012a].
In a study by Krag and colleagues [Krag et al.
2007] of 15 patients with nonrefractory ascites
and 8 with refractory ascites, 2 mg of terlipressin
increased glomerular filtration rate, sodium clearance, lithium clearance, osmolal clearance, und
urinary sodium excretion, and decreased norepinephrine and plasma renin activity, compared
with a placebo infusion. All parameters remained

86 http://tag.sagepub.com

K Lenz, R Buder et al.


Table 2. Treatment of recurrent and refractory ascites.
Diagnosis

Treatment

Recurrent ascites: frequent admission due to


ascites reaccumulation (more than three per year)

Oral clonidine 0.075 mg once to twice daily in


alcoholic cirrhosis with systolic blood pressure
135 mm Hg 20 g albumin/week in addition to
sodium restriction and diuretic treatment
Oral midodrine 75 mg three times daily 20 g
albumin/week in addition to sodium restriction
and diuretic treatment
Intravenous terlipressin 2 mg daily 20 g
albumin /week in addition to sodium restriction
and diuretic treatment
Large-volume paracentesis in nonresponders to
clonidine or midodrine
TIPS in nonresponders to clonidine or midodrine
Large-volume paracentesis together with the
administration of 8 g albumin/l ascitic fluid
removed
TIPS in nonresponders to large-volume
paracentesis

Therapy refractory ascites: no response to dietary


restriction and diuretic treatment

TIPS, transjugular intrahepatic portosystemic shunt.

unchanged after administration of the placebo. In


addition, 2 mg of terlipressin increased water
excretion during a water-loading test in nonazotemic patients with cirrhosis (ChildPugh
classes B and C) but without hyponatremia [Krag
etal. 2007; Kalambokis etal. 2010].
Albumin has been found to be effective for prophylaxis against ascites in small studies. This effect
could be based on the finding of the reduced
function of endogenous albumin in patients with
liver failure [Garcia-Martinez etal. 2013]. A randomized unblinded trial showed that the longterm administration of diuretics plus human
albumin (25 g/week in the first year and 25 g
every 2 weeks thereafter) improved survival and
reduced the risk of recurrence of ascites compared with the administration of diuretics alone
[Romanelli et al. 2006]. However, the relatively
small sample size precluded any firm conclusions.
In a randomized double-blind placebo-controlled
trial, Bari and colleagues [Bari etal. 2012] found
that albumin was not inferior to the combination
of octreotide and midodrine in preventing the
recurrence of ascites after LVP. In addition, the
outcome was worse in patients given octreotide
and midodrine.
Possible treatment options for refractory ascites
include LVP, transjugular intrahepatic portosystemic shunt (TIPS), and liver transplantation
(Table 3). The first-line treatment for patients

with refractory ascites is LVP, wherein a needle is


inserted into the peritoneal cavity to remove the
ascitic fluid [Gines etal. 1987]. This procedure is
easy to perform and safe in most instances.
However, complications are not completely
unknown, and may present after a delay [Martinet
et al. 2000]. Hemorrhagic complications are
infrequent, despite the presence of coagulopathy
in many patients. There are no data on the prophylactic use of fresh-frozen plasma or pooled
platelets, except in patients with a very low platelet count (<40,000/l). However, LVP should be
avoided in the presence of clinically overt disseminated intravascular coagulation. LVP larger than
5 l should be performed with the administration
of albumin to decrease the risk of postparacentesis circulatory dysfunction [Gines et al. 2010].
The dose of albumin most commonly used is 8 g/l
of ascitic fluid removed. However, lower doses
may be effective, which could reduce the cost of
the procedure. In an unblinded study, Allesandria
and colleagues [Allesandria et al. 2011] found
that half the dose of albumin (4 g/l of ascitic fluid
removed) was as effective as the standard dose in
preventing paracentesis-induced circulatory dysfunction and renal failure. However, the most
important factor in avoiding paracentesis-induced
circulatory dysfunction is to discontinue -blocker
therapy [Serste etal. 2010].
In selected patients, a TIPS is an alternative to
serial LVP [Gines et al. 2002]. This procedure

http://tag.sagepub.com 87

Therapeutic Advances in Gastroenterology 8(2)


Table 3. Diagnostic criteria of HRS [Salerno etal. 2007].
Cirrhosis with ascites
Serum creatinine > 1.5 mg/dl
No improvement of serum creatinine (decrease to a level 1.5 mg/dl) after at least 2 days of diuretic
withdrawal and volume expansion with albumin. The recommended dose of albumin is 1 g/kg of body
weight per day up to a maximum of 100 g/day
Absence of shock
No current or recent treatment with nephrotoxic drugs
Absence of parenchymal kidney disease as indicated by proteinuria > 500 mg/day, microhematuria
(> 50 red blood cells per high-power field), and/or abnormal renal ultrasonography

creates a shunt between the portal and suprahepatic veins, thereby reducing portal hypertension
and the rate of recurrence of ascites. Use of a
TIPS is associated with improved systemic hemodynamics and renal function. Many patients with
refractory ascites regain the ability to excrete urinary sodium and can be maintained free of ascites
without sodium restriction or diuretics. In controlled trials comparing paracentesis combined
with intravenous albumin versus a TIPS in patients
with cirrhosis and ascites, the TIPS was clearly
worse, in terms of improvement of ascites and
survival, in patients with refractory ascites than
recurrent ascites [Gines etal. 2002; Lebrec etal.
1996; Rssle etal. 2000; Sanyal etal. 2003]. The
most frequent complication of TIPS use is
encephalopathy [Sanyal etal. 1994]; the incidence
of new or worsening encephalopathy following
TIPS use was found to be 2031% [Salerno etal.
2004; Somberg etal. 1995]. In addition, a TIPS
cannot be applied in some patients with advanced
liver disease (ChildPugh class C), congestive
heart failure, and/or severe pulmonary hypertension owing to an increased risk of mortality, or in
patients with portal thrombosis or inadequate
anatomy of the portal and hepatic veins. Given
that TIPS use is not associated with an improvement in survival, total paracentesis with intravenous albumin for volume replacement is
considered the treatment of choice for refractory
ascites in cirrhosis.
During the past 50 years, several procedures
aimed at improving the treatment of refractory
ascites have been developed [Arroyo, 2013].
Peritoneovenous shunting (PVS) involves a multiperforated intraperitoneal tube connected to a
subcutaneously implanted unidirectional pump
that permits the passage of fluid out of, but not
into, the abdominal cavity, and a second subcutaneous tube that reaches the superior vena cava
through the internal jugular vein [LeVeen et al.
1974]. When ascites is significant, it circulates

through the prosthesis in response to a pressure


gradient (positive in the peritoneum, negative in
the intrathoracic circulation). However, the flow
decreases or even stops if central venous pressure
increases, thus preventing fluid overload. Many
studies have demonstrated that PVS is associated
with major improvements in circulatory and renal
function and a better response to diuretics in
patients with refractory ascites [Gines etal. 1991].
However, these beneficial effects did not result in
a significant improvement in the long-term management of patients or in a reduction in the total
time spent in hospital during follow up, because
of a very high rate of shunt obstruction requiring
reoperation. Moreover, these complications were
not prevented by a redesign of the valve (Denver
shunt) or by insertion of a thromboresistant titanium tip in the vascular end of the prosthesis
[Gines etal. 1995]. Recently, an automated system was developed to remove ascites from the
peritoneal cavity into the urinary bladder, from
which it can be eliminated by normal urination
[Bellot et al. 2013]. The pump system removed
90% of the ascitic fluid and significantly reduced
the median number of LVP sessions per month in
40 patients with recurrent ascites. Larger studies
are needed to confirm the safety and efficacy of
this procedure.
Hepatorenal syndrome
Renal failure is a serious complication in patients
with advanced cirrhosis. It occurs in about 20%
of patients hospitalized with decompensated cirrhosis [Garcia-Tsao et al. 2008; Moore, 2013].
Renal dysfunction is diagnosed based on levels of
creatinine and on creatinine-based equations.
However, a recent study [Francoz et al. 2010]
showed that creatinine-based formulae overestimate the true glomerular filtration rate, especially
in patients with cirrhosis aged under 50 years and
in those with ascites. In about 70% of patients,
renal failure is caused by prerenal failure due to

88 http://tag.sagepub.com

K Lenz, R Buder et al.


Table 4. Diagnostic criteria for kidney dysfunction in cirrhosis using the acute kidney injury definition [Wong etal. 2011].
Diagnosis

Definition

Acute kidney injury


Chronic kidney disease
Acute on chronic kidney
disease

A rise in serum creatinine 50% from baseline, or a rise of >0.3 mg/dl


Glomerular filtration rate (GFR) <60 ml/min for >3 months calculated using the MDRD-6 formula
A rise in serum creatinine 50% from baseline or a rise of serum creatinine >0.3 mg/dl in a patient
with cirrhosis whose GFR is <60 ml/min for >3 months, calculated using the MDRD-6 formula

MDRD-6 formula: GFR = 170 serum creatinine0.999 age0.176 1.180 (if black) 0.762 (if female) serum urea nitrogen0.170 Albumin0.138.

gastrointestinal hemorrhage, bacterial infection,


or hypovolemia (overuse of diuretics), and in
about 30%, it is caused by intrarenal causes, e.g.
hepatitis B- or C-associated glomerulonephritis
or toxins. In about 70% of patients with prerenal
failure, renal function can be restored with fluid
replacement, but the remaining 30% are unresponsive to volume expansion [Garcia-Tsao etal.
2008].
HRS is a fully reversible impairment of renal
function in patients with severe hepatic failure
unresponsive to volume expansion. The prevalence of HRS in patients affected by cirrhosis and
ascites was found to be 18% after 1 year, increasing to 39% at 5 years [Gines and Schrier, 2009].
Before HRS is diagnosed, primary causes of renal
failure, such as hypovolemia, infection, nephrotoxins, and other renal diseases, must be excluded.
Nevertheless, in many patients with HRS lacking
proteinuria or hematuria, some histologic
changes are evident in kidney biopsies [Trawal
etal. 2010]. In almost half of patients with HRS,
one or more precipitating factors were identified,
including bacterial infections (57%), gastrointestinal hemorrhage (36%), and therapeutic paracentesis (7%) [Angeli et al. 2010]. Although a
precipitating event is often identifiable, HRS can
also develop in an apparently spontaneous way.
Spontaneous HRS causes no morphologic
changes in the kidney, although morphologic
alterations in the course of oligoanuria may reveal
a transition from intermediate to irreversible kidney damage with necrosis of the tubules. In
patients with HRS scheduled for liver transplantation, it may be prudent to consider simultaneous kidney transplantation [Restuccia et al.
2004].
HRS is diagnosed by excluding other forms of
renal failure. The diagnostic criteria initially proposed by the International Ascites Club in 1996
were re-examined in 2007 [Salerno et al. 2007]
(see Table 4). Two types of HRS were identified.

Type 1, a rapid deterioration of renal function

defined as an increase in serum creatinine to a


value twice the baseline and >2.5 mg/dl
within 2 weeks.
Type 2, a slow and gradual deterioration of
renal function with serum creatinine
>1.5 mg/dl, often in parallel to the worsening
of cirrhosis and portal hypertension, and leading to refractory ascites.
Pathophysiology
The reduced glomerular filtration rate evident in
patients with HRS is due to poor renal circulation
on the one hand and a reduced filtration fraction
on the other. Several factors are considered to
induce the impairment of renal function (Table 5).
Vasodilation in the splanchnic region
This is considered the most important trigger of
renal hypoperfusion. This vasodilation is associated with enhanced formation of vasodilators
and vascular hyporesponsiveness to vasoconstrictors. To date, several mechanisms have been
identified that may contribute to this enhanced
vasodilation and impaired vasoconstriction.
Portal hypertension increases the production
and release of endogenous vasodilators, such as
nitric oxide, carbon monoxide, and cannabinoids, into the splanchnic arterial circulation,
but other factors seem to be involved as well.
Even in the dormant phase of alcoholic liver disease, vasoactive substances are produced in
large quantities in the liver when the production
of cytokines is increased. In the presence of
endotoxin stimulation, such activation is
increased disproportionately. Even in patients
with nonalcoholic liver disease, infiltration of
endotoxins may play a role. Thus, patients with
HRS prior to liver transplantation exhibited significantly higher concentrations of interleukins
2 and 6 and tumor necrosis factor than patients
lacking HRS before liver transplantation [Burke

http://tag.sagepub.com 89

Therapeutic Advances in Gastroenterology 8(2)


Table 5. Pathomechanism of hepatorenal syndrome.
Underlying causes

Consequences

Splanchnic vasodilation
Central underfilling
Activated volume and baroreceptors

Central underfilling
Activation of volume- and baroreceptors
Increased sympathetic nerve activity, increased
RAAS, increased nonosmotic vasopressin release
Renal vasoconstriction
Abolished autoregulation of the kidney
Activation of the hepatorenal reflex, causing an
increase in renal sympathetic nerve activity and a
decrease in renal blood flow
Compensatory increase in cardiac output to
maintain renal perfusion is lowered
Intrarenal vasoconstriction

Increased sympathetic activity, increased RAAS,


increased nonosmotic vasopressin release
Increased intrahepatic pressure and decreased
sinusoidal blood flow
Cardiac insufficiency
Increased synthesis of vasoactive mediators
RAAS, reninangiotensinaldosterone system.

etal. 1993]. Furthermore, increased endothelin


concentrations have been observed, and regulatory disorders of the adenosine system have also
been discussed [Gerbes et al. 1998].
Translocation of bacteria and bacterial products
from the gut is likely to be a main factor underlying the development of a chronic inflammatory state [Israelsen et al. 2014]. Another
mechanism seems to be defective contractile
signaling in smooth muscle cells in response to
vasoconstrictor stimulation [Hennenberg et al.
2008]. In addition to the liver itself, little is
known about the factors responsible for these
defects. The consequences are vasodilation,
increased plasma volume, and increased blood
flow in the splanchnic circulation, leading to a
reduction in the effective arterial blood volume
and a drop in arterial pressure. Vasodilation is
associated with increased mesenteric blood flow,
which may in fact be a useful mechanism to
maintain liver function. In one study, liver function in patients who underwent transplantation
for liver failure was found to be dependent on
the in-vitro liver circulation [Cardoso et al.
1994].
Central underfilling
In the early stages of cirrhosis, increased cardiac
output compensates for the reduction in systemic
vascular resistance caused by vasodilation in the
splanchnic area, and allows arterial pressure and
effective blood volume to remain within normal
limits. In the advanced stages of cirrhosis, splanchnic vasodilation is markedly increased, and additional increases in cardiac output can no longer

compensate, leading to central underfilling.


Central underfilling activates baro and volume
receptors, with consequent stimulation of the
sympathetic nervous system and RAAS and the
nonosmotic release of vasopressin. This results in
renal hypoperfusion caused by an increase in
renal vascular resistance [Lenz etal. 1991], reabsorption of sodium in the tubules, and increased
reabsorption of water in the distal collecting
tubules.
Abolished autoregulation of kidney perfusion
Increased sympathetic nervous system activity
abolishes autoregulation in the kidney [Esler and
Kye, 1998]. Consequently, the renal circulation
becomes pressure-dependent, even in the presence of physiologic blood pressure [Stadlbauer
et al. 2008]. This is because the mean arterial
blood pressure at which renin starts to be released
is shifted to <110 mmHg [Kirchheim and Ehmke,
1994; Persson etal. 1990].
Hepatorenal reflex
In cirrhosis, sinusoidal pressure is elevated by
increased resistance and enhanced mesenteric
blood flow. Elevated pressure, secondary to swelling in the course of glutamine infusion via the
superior mesenteric artery, led to a reduction of
renal circulation and the glomerular filtration
rate. This was due to direct hepatorenal interaction [Lang et al. 1991]. Increased intrahepatic
pressure leads to enhanced activity of sympathetic
efferents from the liver that, through synapses in
the lumbar spinal cord, cause enhanced renal

90 http://tag.sagepub.com

K Lenz, R Buder et al.


sympathetic activity (the hepatorenal reflex
[Kostreva etal. 1980]). A decrease in sinusoidal
blood flow also triggers the hepatorenal reflex
[Ming et al. 2002]. An increase in renal sympathetic nerve activity leads to renal vasoconstriction and increased tubular sodium reabsorption.
Denervation of the kidney eliminates this renal
sympathetic activity, thereby reducing the impairment of renal function. This can also be achieved
by hepatic vagal denervation [Levy and Wexler,
1987]. In a clinical study, Solis-Herruzo and colleagues [Solis-Herruzo et al. 1987] were able to
interrupt the hepatorenal reflex with lumbar sympathetic block in patients with portal hypertension and thereby improve renal function.
Cardiac insufficiency
An increase in cardiac output is important to
compensate for the reduction in systemic vascular
resistance caused by vasodilation in the splanchnic area, and permits the arterial pressure and
effective blood volume to remain within normal
limits. There is evidence that cardiac output
decreases as cirrhosis progresses. Clinical, but not
overt, cardiac insufficiency, caused by underlying
viral diseases, toxins such as alcohol, and/or by
cirrhotic cardiomyopathy per se, seems to be one
of the leading risk factors for the development of
HRS. Ruiz-del-Arbrol and colleagues [Ruiz-delArbrol et al. 2005] showed that cardiac insufficiency can be detected at an early stage in patients
developing HRS. In addition, the use of -blockers
in patients with refractory ascites has been shown
to be deleterious [Serste etal. 2010]. These findings suggest a cardiorenal link in advanced cirrhosis (Krag etal. 2012b).
Relative adrenal insufficiency
This is a common subclinical condition in patients
with cirrhosis, and is diagnosed as an inadequate
production of cortisol in response to stimulation
with synthetic adrenocorticotropic hormone.
Adrenal insufficiency increases the risk of bacterial infection, septic shock, and HRS [Acevedo
et al. 2013]. Cortisol plays an important role in
hemodynamic homeostasis: the response of the
heart and blood vessels to catecholamines and
angiotensin-II is increased by cortisol. Low levels
of cortisol lead to an inadequate increase in cardiac output and insufficient vasoconstriction in
response to stress. Accordingly, adrenal insufficiency may be involved in the development of cardiomyopathy and HRS [Krag etal. 2012].

Treatment of renal failure


Treatment should begin as soon as renal failure is
diagnosed. The criteria for diagnosis of HRS may
lead to renal failure being detected too late
[Nadim etal. 2012]. In addition, creatinine-based
formulae may overestimate the true glomerular
filtration rate, because of the low levels of muscle
proteins in patients with cirrhosis and ascites
[Francoz etal. 2010]. Cystatin C-based equations
have proven more accurate in the evaluation of
renal function and the staging of chronic renal
insufficiency [De Souza et al. 2014]. Use of the
new definition of acute kidney injury (AKI) developed by the Acute Kidney Injury Network as
adapted for cirrhotic patients [Wong etal. 2011]
(Table 6) allows renal failure to be identified
much earlier [Moore, 2013]. A prospective observational cohort study of patients with cirrhosis
and AKI showed that AKI is frequently progressive and associated with mortality [Belcher etal.
2013]. Therefore, the early identification and
treatment of its cause are the cornerstones of
therapy (Table 6). This includes withdrawal of
-blockers in patients with end-stage cirrhosis
[Krag et al. 2012], discontinuation of nonsteriodal drugs and diuretics and, in patients with
hypovolemia due to bleeding, prompt treatment
with fluids and blood products combined with
measures to stop the bleeding [Baradarian et al.
2004].
To treat hypovolemia, the recommended dose of
albumin is 1 g/kg body weight in all patients after
at least 2 days of diuretic withdrawal [Salerno
et al. 2007]. However, because the degree of
hypovolemia varies between patients, a more precise estimation of the volume required appears
logical. Indeed, using invasive instruments,
Umgelter and colleagues [Umgelter et al. 2012]
demonstrated that much more fluid (up to 2 g
albumin/kg body weight) may be necessary to
normalize renal function. The main problem in
clinical practice is that invasive hemodynamic
monitoring can only be performed in intensive
care units. Nevertheless, if there are clinical signs
that 1 g albumin/kg is inadequate, more fluid can
be infused under the careful observation of noninvasive hemodynamic parameters and lung
function.
Antiviral therapy may be effective in some patients
with renal failure due to hepatitis C-related glomerulonephritis after consideration of the possible
adverse effects of this therapy in patients with
advanced cirrhosis and hepatitis B virus-associated

http://tag.sagepub.com 91

Therapeutic Advances in Gastroenterology 8(2)


Table 6. Prophylaxis against hepatorenal system.

Prompt and adequate treatment of hypovolemic situations


Albumin substitution in spontaneous bacterial peritonitis (SBP)
Albumin substitution with large-volume paracentesis
Antibiotic prophylaxis in patients at increased risk of SBP
Withdrawal of -blockers in patients with cirrhosis with recurrent and refractory ascites
Withdrawal of nonsteroidal drugs in portal decompensation
Nephroprophylaxis in patients with cirrhosis when radiologic studies using contrast medium are
performed

kidney injury [Gane et al. 2014]. Bacterial infections must be identified and treated early. In
patients with SBP, the addition of albumin (1.5 g/kg
body weight at the time of diagnosis, followed by 1
g/kg on day 3) to antibiotic treatment reduces the
incidence of renal failure [Salerno etal. 2013; Sort
etal. 1999].
Ascites is a risk factor for the development of contrast-induced nephropathy. Although no reports
show that cirrhosis without ascites is a risk factor,
all patients with cirrhosis who undergo radiologic
studies and require contrast medium should
receive standard prophylactic saline hydration
[Lodhia etal. 2009]. A recent study [Mahmoodi
etal. 2014] involved patients with coronary heart
disease and chronic renal failure with a serum
creatinine level of up to 4 mg/dl who were undergoing coronary intervention, use of a bicarbonate
solution (prepared by adding 154 ml of 1000
mEq/l sodium bicarbonate to 846 ml of 5% dextrose in water) conferred greater protection than
hydration with normal saline against contrastinduced AKI. However, because metabolic alkalosis, mostly due to low albumin concentration, is
a frequent finding in liver failure [Funk et al.
2006], further studies are required in patients
with cirrhosis to confirm these results.

in the short term, but this effect is no longer evident after 6 months [Mathurin etal. 2013]. Oral
antibiotics are effective in reducing the incidence
of HRS in patients with advanced cirrhosis and
ascites. In a randomized placebo-controlled study,
primary prophylaxis with norfloxacin reduced the
incidence of SBP and delayed the development of
HRS in patients with cirrhosis, low-protein ascitic
fluid (<15 g/l), and advanced liver failure (Child
Pugh score >9) [Fernandez etal. 2007].
Knowledge of the pathophysiologic features of
HRS has led to a variety of therapeutic approaches.
It would be logical to assume that renal function is
improved by substances that abolish renal vasoconstriction. However, experiments performed
with prostaglandin to date have produced divergent results [Wong et al. 1994]. Likewise, the
administration of dopamine achieves improvements in cirrhotic patients with relatively good
renal function, but not in patients with massively
impaired renal function [Bennet etal. 1975; Peschl,
1987]. In patients with cirrhosis, renal failure, and
tense ascites, increased abdominal pressure (IAP)
may contribute to renal dysfunction. Reduction of
IAP following paracentesis and albumin substitution improves renal function, probably by improving renal blood flow [Umgelter etal. 2009).

In end-stage cirrhosis, -blockers may reduce


survival owing to their negative impact on the cardiac compensatory reserve. The inability to
increase cardiac output may compromise organ
perfusion in these patients [Krag etal. 2012]. The
use of -blockers is associated with increased
mortality in patients with refractory ascites at
high risk of paracentesis-induced circulatory dysfunction [Serste et al. 2010]. Although data on
this subject are scarce, the use of -blockers
should be avoided in patients with both cirrhosis
and renal failure.

The current therapeutic approach to HRS


includes the administration of vasoconstrictive
agents combined with albumin (Table 7). The
effect of vasopressors on renal function in this
situation is due to an increase in renal perfusion,
resulting from increased central blood volume
and elevated blood pressure. Given that autoregulation is diminished, increased blood pressure is
associated with increased renal perfusion. An
inadequate blood-pressure response to vasopressor therapy is a typical finding in nonresponders
[Nazar etal. 2011; Velez and Nietert, 2011].

Pentoxifylline has been shown to reduce the risk


of renal failure in patients with alcoholic hepatitis

The available vasoconstrictors comprise vasopressin analogues and alpha-adrenergic agents such as

92 http://tag.sagepub.com

K Lenz, R Buder et al.


Table 7. Treatment of hepatorenal syndrome.
Drug

Dose

Terlipressin

Bolus: 0.52.0 mg intravenously every 46 hours, with stepwise dose


increments if there is no improvement of serum creatinine, to a maximum
of 12 mg/day or the occurrence of complications, in combination with
albumin.
Continuous infusion: 4 mg/day with stepwise dose increments if there is
no increase in mean arterial blood pressure >10 mmHg or improvement
in serum creatinine level, up to a maximum of 12 mg/day or the
occurrence of complications, in combination with albumin.

Noradrenaline

Continuous infusion with a starting dose of 0.5 mg/h, with stepwise


increments if there is no increase in mean arterial blood pressure
>10 mmHg or improvement of serum creatinine level, up to a maximum
of 3 mg/h or the occurrence of complications, in combination with
albumin.

Midodrine plus octreotide

Oral midodrine 7.512.5 mg three times daily to increase mean arterial


blood pressure >10 mmHg.
Octreotide 200 g subcutaneously three times daily.

Albumin

1 g albumin/kg body weight on the first day, followed by 200400 g daily.

noradrenaline and midodrine. The first studies


were performed with octapressin, a vasopressin
derivative, more than 40 years ago [Kew et al.
1972]. Over 30 years ago, ornipressin (8-ornithinevasopressin: a vasopressin derivative that predominantly stimulates the vasopressin 1 receptor) was
found to improve central hypovolemia through
splanchnic vasoconstriction, leading to decreased
activation of vasopressor hormones (norepinephrine and renin) and decreased renal vascular resistance, resulting in improved renal perfusion in
patients with cirrhosis and HRS [Lenz etal. 1991].
Because ornipressin was removed from the market,
subsequent studies were performed using terlipressin. Terlipressin is a triglycyl-lysine-vasopressin
with a vasoconstrictive effect per se when given as a
bolus and an additional long-acting vasoconstrictive effect caused by lysine-vasopressin, which is
produced by triglycyl-lysine-vasopressin degradation [Ryckwaert etal. 2009]. Vasopressors such as
terlipressin induce vasoconstriction in the splanchnic vasculature by acting on vasopressin 1 receptors, resulting in redistribution of blood flow to the
kidneys. Vasopressin analogues have been shown to
decrease serum levels of vasoconstrictor hormones
such as norepinephrine and plasma renin activity,
leading to a decrease in renal vascular resistance
[Lenz etal. 1991]. The vasopressin analogue terlipressin has been shown not only to improve renal
function by peripheral actions, but also to significantly influence cardiac filling volumes [Krag etal.
2010]. In experimental ovine endotoxemia, intermittent bolus injections of terlipressin were linked

to decreased heart rate and cardiac index and


increased
pulmonary
vascular
resistance.
Continuous infusion of terlipressin reversed endotoxin-induced systemic arterial hypotension and
improved left-ventricular stroke-work index [Lange
etal. 2007]. Therefore, continuous administration
of terlipressin may be superior to bolus injection.
Norepinephrine has a positive inotropic effect,
which may be important in overcoming the cardiac insufficiency induced by chronic liver disease.
In patients with portal hypertension, terlipressin
increased thoracic and liver blood volumes and
altered portal pressure by causing vasodilation of
intrahepatic vessels [Kiszja-Kanowith etal. 2004].
The effect of terlipressin can be significantly
enhanced by the addition of high doses of human
albumin [Ortega etal. 2002]. Although the favorable effect of albumin in this context is traditionally linked to its role in volume replacement, other
mechanisms related to its nononcotic properties
are likely to be involved. Albumin binds to and
carries a variety of hydrophilic and hydrophobic
molecules, including metals, fatty acids, metabolites, and drugs. Many potentially toxic ligands
are neutralized and catabolized by binding to
albumin. Furthermore, albumin is the major
source of extracellular reduced sulfhydryl groups,
potent scavengers of reactive oxygen species generated by oxidative stress; thus, albumin is the
main circulating antioxidant in the body. Recent
studies have shown that both albumin

http://tag.sagepub.com 93

Therapeutic Advances in Gastroenterology 8(2)


concentration and function are reduced in
patients with cirrhosis [Jalan and Bernardi, 2013],
and that the degree of albumin dysfunction is
related to the prognosis of liver disease [Jalan and
Bernardi, 2013; Oettl et al. 2013]. In addition,
albumin has been shown to have a positive cardiac inotropic effect in cirrhotic rats [Bortoluzzi
et al. 2013]. Substitution of albumin therefore
seems to accomplish more than plasma
expansion.
Many studies have been performed with terlipressin. Meta-analyses have demonstrated that the
combination of terlipressin and albumin improves
renal function in patients with HRS type 1 [Nazar
etal. 2011; Neri etal. 2008] and reduces mortality when compared with albumin alone. The
reduction in mortality was evident in patients
with type I, but not type II, HRS [Gluud et al.
2010]. Therefore, terlipressin plus albumin may
facilitate survival to transplantation and a better
outcome after transplantation, because normalization of renal function before transplantation is
associated with increased survival after transplantation [Restuccia etal. 2004]. In these studies, a
fixed dose of 1 g albumin/kg body weight on the
first day, with a reduction to 2040 g on subsequent days, was used. Terlipressin was started on
the first day at a dose of 0.5 mg every 46 hours,
with an increase to a maximum of 12 mg per day
until improvement of renal function occurred,
defined as a serum creatinine concentration of
<1.25 mg/dl. An improvement was seen within
14 days [Martin-Llahi et al. 2008; Neri et al.
2008; Sanyal etal. 2008]. Predictors of improved
renal function in patients with HRS include early
stage renal failure, increased blood pressure
induced by the vasopressor, normal sodium concentration, and ChildPugh score <11 [Boyer
etal. 2011; Nazar etal. 2011; Velez and Nietert,
2011; Wong et al. 2004]. Given that larger
amounts of albumin-containing fluids have been
shown to restore kidney function more effectively
[Umgelter et al. 2012], goal-oriented volume
therapy, using serial echocardiography to assess
changes in intravascular volume by measuring
inferior vena caval diameter, right-ventricular
end-diastolic volume index, left-ventricular enddiastolic area index, and global end-diastolic volume index, may be useful [Charron etal. 2006],
although studies on cirrhotic patients are scarce.
Also controversial are the parameters for titrating
the dose of terlipressin. Given that a close relationship exists between hemodynamics and the

improvement of renal function [Nazar etal. 2011;


Velez and Nietert, 2011], an increase in mean
arterial pressure of 10 mmHg, as used in studies with norepinephrine, may help to achieve an
earlier improvement in renal function [Maddukuri
et al. 2014]. Adverse effects of terlipressin (predominately ischemia) leading to the discontinuation of treatment occur in about 12% of patients
[Fagundes and Gines, 2012]. Therefore, patients
with coronary heart disease, peripheral vascular
disease, and/or cerebrovascular disease should
not be treated with terlipressin. Some of these
complications may be caused by the bolus injection, because of the acute effect of the prodrug
[Ryckwaert et al. 2009]. A continuous infusion
may overcome this problem [Angeli etal. 2009].
Studies on endotoxic shock in animal models, in
which continuous infusion of terlipressin exerted
a superior effect on cardiac contractility than
bolus injection [Lange et al. 2007], support the
advantages of continuous infusion of terlipressin.
Alpha-adrenergic agonists, such as norepinephrine [Sharma et al. 2008; Singh et al. 2012] or
midodrine, in combination with octreotide and
albumin [Angeli et al. 1999; Skagen et al. 2009;
Wong etal. 2004], are a reasonable alternative to
terlipressin because of their low cost and wide
availability. However, data on their use are limited. They are recommended in the guidelines of
the American Association for the Study of Liver
Diseases (AASLD) because terlipressin is not yet
available in the United States [Runyon, 2012],
but they are not recommended by the European
Association for the Study of the Liver (EASL)
[Gines etal. 2010]. If HRS reoccurs after the discontinuation of treatment, patients should be
retreated with the same drug combination [Gines
etal. 2010].
TIPS use was reported to be effective for HRS
Type 1 in an uncontrolled study of a small group
of patients [Guevara et al. 1998]. Insertion of a
TIPS further improved renal function and sodium
excretion in patients with HRS type 1, who
responded to a combination of midodrine, octreotide, and albumin [Wong et al. 2004]. More
studies are necessary to evaluate TIPS use in
patients with HRS type 1. TIPS use is not recommended in the guidelines of the EASL or AASLD.
Type 2 HRS is a type of renal dysfunction that
arises from the deterioration of several organ systems, and is primarily caused by liver failure and
portal hypertension. It is part of a gradually

94 http://tag.sagepub.com

K Lenz, R Buder et al.


developing multiorgan dysfunction, with central
hypovolemia and cardiac dysfunction as the main
pathogenic triggers [Lenz, 2005]. There are very
few data about the use of vasopressors in combination with albumin in patients with HRS type 2.
The clinical picture is dominated by therapy for
refractory ascites and hyponatremia. Therefore,
repeated paracentesis is the first-choice treatment; if renal function is deteriorating, the use of
vasopressors should be considered [Fagundes
and Gines, 2012]. Patients must be evaluated to
determine whether they are candidates for liver
transplantation.
Renal replacement therapy (RRT) has been used
in patients with type 1 HRS waiting for liver
transplantation. There are no data comparing
extracorporeal therapy with vasopressors plus
albumin in patients with HRS; nevertheless, RRT
is not considered to be a first-line treatment,
because it does not correct the underlying pathophysiologic changes. RRT should be reserved for
patients planned for liver transplantation. The
mortality of patients with HRS treated with
hemodialysis or hemofiltration in the intensive
care unit is reportedly high [Witzke etal. 2004].
In a small study [Mitzner etal. 2000], improvement of renal function followed use of an extracorporeal liver assist system (MARS). However,
in the recently published RELIEF trial, MARS
therapy did not demonstrate a positive effect on
patients with acute or chronic liver failure
[Banares etal. 2013]. EASL guidelines state that
RRT may be useful in patients who do not
respond to vasoconstrictor therapy [Gines et al.
2010]. It remains unclear what modality of RRT
should be the first-choice treatment for pharmacologic nonresponders awaiting transplantation.
Conflict of interest statement
The authors declare that they do not have anything to disclose regarding conflicts of interest
with respect to this manuscript.
Funding
This research received no specific grant from any
funding agency in the public, commercial, or notfor-profit sectors.

References
Acevedo, J., Fernandez, J., Prado, V., Silva, A.,
Castro, M., Pavesi, M. etal. (2013) Relative adrenal
insufficiency in decompensated cirrhosis: relationship

to short-term risk of severe sepsis, hepatorenal


syndrome, and death. Hepatology 58: 17571765.
Allesandria, C., Ella, C., Mezzabitta, L., Risso, A.,
Andrealli, A., Spandre, M., Morgando, A. etal.
(2011) Prevention of paracentesis-induced circulatory
dysfunction in cirrhosis: Standard vs half albumin
doses. A prospective, randomized, unblinded study.
Digest Liver Dis 43: 881886.
Angeli, P., Dalla Pria, M., De Bei, E., Albino, G.,
Caregaro, L., Merkel, C. etal. (1994) Randomized
clinical study of the efficacy of amiloride and
potassium canrenoate in nonacotemic cirrhotic
patients with ascites. Hepatology 19: 7279.
Angeli, P., Fasolato, S., Cavalllin, M., Trotta, E.,
Maresio, G., Callegaro, A. etal. (2009) Terlipressin
given as continuous intravenous versus terlipressin
given as intravenous boluses in the treatment of type
1 hepatorenal syndrome (HRS) in patients with
cirrhosis. J Hepatol 50(Suppl. 1): S73.
Angeli, P., Fasolato, S., Mazza, E., Okolicsanyi, L.,
Maresio, G., Velo, E. etal. (2010) Combined versus
sequential diuretic treatment of ascites in nonazotaemic patients with cirrhosis: results of an open
randomised clinical trial. Gut 59: 98104.
Angeli, P. and Morando, F. (2010) Optimal
management of hepatorenal syndrome in patients with
cirrhosis. Hepatic Med Evid Res 2: 8798.
Angeli, P., Volpin, R., Gerunda, G., Maresio, G.,
Callegano, A., Galieto, A. etal. (1999) Reversal
of type 1 hepatorenal syndrome (HRS) with the
combined administration of midodrine and octreotide.
Hepatology 29: 16901697.
Angeli, P., Volpin, R., Piovan, D., Bortoluzzi, A.,
Craighero, R., Bottaro, S. etal. (1998) Acute effects of
the oral administration of midodrine, an alpha-adrenergic
agonist, on renal hemodynamics and renal function in
cirrhotic patients with ascites. Hepatology 28: 937943.
Angeli, P., Wong, F., Watson, H. and Gines, P.
(2006) Hyponatremia in cirrhosis: Results of a patient
population survey. Hepatology 44: 15351542.
Arroyo, V. (2013) A new method for therapeutic
paracentesis: The automated low flow pump
system. Comments in the context of the history of
paracentesis. J Hepatol 58: 850852.
Banares, R., Nevens, F., Larsen, F., Jalan, R.,
Albillos, A., Dollinger, M. etal. (2013) Extracorporeal
albumin dialysis with the molecular adsorbend
recirculating system in acute-on-chronic liver failure.
The RELIEF trial. Hepatology 57: 11531162.
Baradarian, R., Ramdhaney, S., Chapalamadugu,
R., Skoczylas, L., Wang, K., Rivilis, S. etal. (2004)
Early intensive resuscitation of patients with upper
gastrointestinal bleeding decreases mortality. Am J
Gastroent 9: 619622.

http://tag.sagepub.com 95

Therapeutic Advances in Gastroenterology 8(2)


Bari, K., Minano, C., Shea, M., Inayat, I., Hasehm,
H., Gilles, H. etal. (2012) The combination of
octreotide and midodrine is not superior to albumin
in preventin recurrence of ascites after large-volume
paracentesis. Clin Gastroenterol Hepatol 10: 1169
1175.
Becker, E. (2011) Diagnosis and therapy of ascites in
liver cirrhosis. World J Gastroenterol 17: 12371248.
Belcher, J., Garcia-Tsao, G., Sanyal, A., Bhogal, H.,
Lim, J., Ansar, N. etal. (2013) Association of AKI
with mortality and complications in hospitalized
patients with cirrhosis. Hepatology 57: 753762.
Bellot, P., Welker, M., Soriano, G., von Schaewen,
M., Appenrodt, B., Wiest, R. etal. (2013) Automated
low flow pump systems for the treatment of refractory
ascites: A multicenter safety and efficacy study. J
Hepatol 58: 922927.
Bennet, W., Keeffe, E., Melnyk, C., Mahler, D.,
Rsch, D., Rsch, J. etal. (1975) Response to
dopamine hydrochloride in the hepatorenal syndrome.
Arch Intern Med 135: 964970.
Bernardi, M., Serfadeo, D., Trevisani, F., Rusticali,
A. and Gasbarrini, G. (1985) Importance of plasma
aldosterone concentration on the natriuretic effect
of spironolactone in patients with liver cirrhosis and
ascites. Digestion 31: 189193.
Bortoluzzi, A., Ceolotto, G., Gola, E., Sticca, A,
Bova, S., Morando, F. etal. (2013) Positive cardiac
inotropic effect of albumin infusion in rodents
with cirrhosis and ascites: molecular mechanisms.
Hepatology 57: 266276.
Boyer, T., Sanyal, A., Garcia-Tsao, G., Blei, A., Carl,
D., Bexon, A. etal. (2011) Predictors of response to
terlipressin plus albumin in hepatorenal syndrome
(HRS) type 1: Relationship of serum creatinine to
hemodynamics. J Hepatol 55: 315321.
Burke, G., Cirocco, R., Roth, D., Fernandez, J.,
Allouche, M., Mardkou, M. etal. (1993) Activated
cytokine pattern in hepatorenal syndrome: Fall in
levels after successful orthotopic liver transplantation.
Transplant Proc 25: 18761877.
Cardenas, A., Gines, P., Marotta, P., Czerwiec, F,
Oyuang, J., Guevara, M. etal. (2012) Tolvaptan
an oral vasopressin antagonist, in the treatment of
hyponatremia in cirrhosis. J Hepatol 56: 571578.
Cardoso, J., Gautreau, C., Jeyaraj, P., Patrzalek,
D., Cherruau, B., Vauvourdolle, M. etal. (1994)
Augmentation of portal blood flow improves
function of human cirrhotic liver. Hepatology 19:
375380.
Charron, C., Caille, V., Jardin, F. and VieillardBaron, A. (2006) Echocardiographic measurement
of fluid responsiveness. Curr Opin Crit Care 12:
249254.

DAmico, G., Garcia-Tsao, G. and Pagliaro, L.


(2006) Natural history and prognostic indicators of
survival in cirrhosis. J Hepatol 44: 217231.
Decaux, G. and Vassart, G. (2008) Non-peptide
arginine vasopressin antagonists: the vaptanes. Lancet
371: 16241632.
De Souza, V., Hadj-Aissa, A., Dolomanova, O.,
Rabilloud, M., Rognant, N., Lemoine, S. etal. (2014)
Creatinine-versus cystatine C-based equations in
assessing the renal function of candidates for liver
transplantation with cirrhosis. Hepatology 59: 15221531.
Esler, M. and Kye, D. (1998) Increased sympathetic
nervous system activity and its therapeutic reduction
in arterial hypertension, portal hypertension and heart
failure. J Auton Nerv Syst 72: 210219.
Fagundes, C. and Gines, P. (2012) Hepatorenal
syndrome: A severe, but treatable cause of kidney
failure in cirrhosis. Am J Kidney Dis 59: 874885.
Fernandez, J., Navasa, M., Planas, R., Montoliu,
S., Monfort, D., Doriano, G. etal. (2007) Primary
prophylaxis of spontaneous bacterial peritonitis delays
hepatorenal syndrome and improves survival in
cirrhosis. Gastroenterology 133: 818827.
Francoz, C., Prie, D., AbdelRazek, W., Moreau, R.,
Mandot, A., Belghitti, J. etal. (2010) Inaccuracies
of creatinine and creatinine based equations
in candidates for liver transplantation with low
creatinine: Impact on the model for endstage liver
disease score. Liver Transplant 16: 11691177.
Funk, G., Doberer, D., Fuhrmann, V., Holzinger,
U., Kitzberger, R., Kneidinger, N. etal. (2006)
The acidifying effect of lactate is neutralized by
the alkalinizing effect of hypoalbuminemia in nonparacetamol-induced acute liver failure. J Hepatol 45:
387392.
Gane, E., Deray, G., Liaw, Y., Lim, S., Lai, C.,
Rasenack, J. etal. (2014) Telbivudine improves
renal function in patients with chronic hepatitis B.
Gastroenterology 146: 138146.
Garcia-Martinez, R., Caracenni, P., Bernardi, M.,
Gines, P., Arroyo, V. and Jalan, R. (2013) Albumin:
Pathophysiologic basis of its role in the treatment
of cirrhosis and its complications. Hepatology 58:
18361846.
Garcia-Tsao, G., Chirag, R. and Antonella, V. (2008)
Acute kidney injury in cirrhosis. Hepatology 48:
20642077.
Gerbes, A., Glber, V. and Bilzer, M. (1998)
Endothelin and other mediators in the
pathophysiology of portal hypertension. Digestion
59(Suppl. 2): 810.
Gianotti, R. and Cardenas, A. (2014) Hyponatraemia
and cirrhosis. Gastroenterol Rep 2: 2126.

96 http://tag.sagepub.com

K Lenz, R Buder et al.


Gines, P., Angeli, P., Lenz, K., Moller, S., Moore,
K. and Moreau, R. (2010) EASL clinical practice
guidelines on the management of ascites, spontaneous
bacterial peritonitis, and hepatorenal syndrome in
cirrhosis. J Hepatol 53: 397417.
Gines, P., Arroyo, V., Quintero, E., Planas, R.,
Bory, F., Cabrera, J. etal. (1987) Comparison
of paracentesis and diuretics in the treatment of
cirrhotics with tense ascites: results of a randomized
study. Gastroenterology 93: 234241.
Gines, P., Arroyo, V., Vargas, V., Planas, R.,
Casafont, F., Panes, J. etal. (1991) Paracentesis with
intravenous infusion of albumin as compared with
peritoneovenous shunting in cirrhosis with refractory
ascites. N Engl J Med 325: 829835.
Gines, A., Planas, R., Angeli, P., Guarner, C.,
Salerno, F., Gines, P. etal. (1995) Treatment of
patients with cirrhosis and refractory ascites by
LeVeen shunt with titanium tip. Comparison with
therapeutic paracentesis. Hepatology 22: 124131.
Gines, P. and Schrier, R. (2009) Renal failure in
cirrhosis. N Engl J Med 361: 12791290.
Gines, P., Uriz, J., Calahorra, B., Garcia-Tsao,
G., Kamath, P., Ruiz-del-Arbol, L. etal. (2002)
Transjugular intrahepatic portosystemic shunting
versus paracentesis plus albumin for refractory ascites
in cirrhosis. Gastroenterology 123: 18391847.
Gluud, L., Christensen, K., Christensen, E. and
Krag, A. (2010) Systemic review of randomized trials
of vasoconstrictor drugs for hepatorenal syndrome.
Hepatology 51: 576584.
Guevara, M., Gines, P., Bandi, C., Gilabert, R., Sort,
P., Jimenez, W. etal. (1998) Transjugular intrahepatic
portosystemic shunt in hepatorenal syndrome: effects
on renal function and vasoactive systems. Hepatology
28: 416422.
Hennenberg, M., Trebicka, J., Sauerbruch, T.
and Heller, J. (2008) Mechanisms of extrahepatic
vasodilation in portal hypertension. Gut 57: 1300
1314.
Israelsen, M., Gluud, L. and Krag, A. (2014) Acute
kidney injury and hepatorenal syndrome in cirrhosis. J
Gastroenterol Hepatol. DOI: 10.1111/jgh.12709.
Jalan, R. and Bernardi, M. (2013) Effective albumin
concentration and cirrhosis mortality from concept to
reality J Hepatol 59: 918920

decompensated cirrhosis is associated with increased


mortality. Hepatology 50: 555564.
Kalambokis, G., Pappas, K., Baltayiannis, G.,
Katsanou, A. and Tsianos, E. (2010) Effects of
terlipressin on water excretion after oral water load
test in nonazotemic cirrhotic patients with ascites
without hyponatremia. Scand J Gastroenterol 45:
15091515.
Kew, M., Varma, R., Sampson, D. and Sherlock,
S. (1972) The effect of octapressin on renal and
intrarenal blood flow in cirrhosis of the liver. Gut 33:
1420.
Kirchheim, H. and Ehmke, H. (1994) Vasoactive
hormones: modulators of renal function. Clin Invest
72: 685687.
Kiszja-Kanowith, M., Henriksen, J., Hansen,
E., Moller, S. and Bendtsen, F. (2004) Effect of
terlipressin on blood volume distribution in patients
with cirrhosis. Scand J Gastroenterol 39: 486492.
Kostreva, D., Castaner, A. and Kampine, J. (1980)
Reflex effects of hepatic baroreceptors on renal and
cardiac sympathetic nerve activity. Am J Physiol 238:
R390R394.
Krag, A., Bendtsen, F., Burroughs, A. and Moller,
S. (2012) The cardiorenal link in advanced cirrhosis.
Med Hypoth 79: 5355.
Krag, A., Bendtsen, F., Mortensen, C., Henriksen, J.
and Moller, S. (2010) Effects of a single terlipressin
administration on cardiac function and perfusion in
cirrhosis. Eur J Gastroenterol Hepatol 22: 10851092.
Krag, A., Moller, S., Henriksen, J., Holstein-Rathlou,
N., Larsen, F. and Bendtsen, F. (2007) Terlipressin
improves renal function in patients with cirrhosis and
ascites without hepatorenal syndrome. Hepatology 46:
18631871.
Krag, A., Wiest, R., Albillos, A. and Gluud, L.
(2012) The window hypothesis: haemodynamic and
nonhaemodynamic effects of -blockers improve
survival of patients with cirrhosis during a window in
the disease. Gut 61: 967969.
Laenaerts, A., Codden, T., Meunier, J., Henry,
J. and Ligny, G. (2006) Effects of clonidine on
diuretic response in ascitic patients with cirrhosis and
activation of sympathetic nervous system. Hepatology
44: 844849.

Jalan, R., Mookerjee, R., Cheshire, L., William, R.


and Davies, N. (2007) Albumin infusion for severe
hyponatremia in patients with refractory ascites: a
randomized clinical trial. J Hepatol 46(Suppl. 1): S95.

Laenerts, A., Coddon, T., Van Cauter, J.,


Moukhaiber, H., Meunier, J. and Ligny, G. (1997)
Treatment of refractory ascites with clonidine
and spironolactone. Gastroenterol Clin Biol 21:
524525.

Jalan, R., Schnurr, K., Mookerjee, R., Sen, S.,


Cheshire, L., Hodges, S. etal. (2009) Alterations in
the functional capacity of albumin in patients with

Lang, F., Tschernko, E., Schulze, E., ttl, I.,


Ritter, M, Vlkl, H. etal. (1991) Hepatorenal reflex
regulating kidney function. Hepatology 14: 590594.

http://tag.sagepub.com 97

Therapeutic Advances in Gastroenterology 8(2)


Lange, M., Morelli, A., Ertmer, C., Koehler,
G., Brking, K., Hucklenbruch, C. etal. (2007)
Continuous versus bolus infusion of terlipressin in
ovine endotoxemia. Shock 28: 623629.

McCormick, P., Mistry, P., Kaye, G., Burroughs,


A. and McIntyre, N. (1990) Intravenous albumin
infusion is an effective therapy for hyponatraemia in
cirrhotic patients with ascites. Gut 31: 204207.

Lebrec, D., Giuily, N., Hadengue, A., Vilgrain, V.,


Moreau, R., Poynard, T. etal. (1996) Transjugular
intrahepatic portosystemic shunts: comparison with
paracentesis in patients with cirrhosis and refractory
ascites: a randomized trial. J Hepatol 25: 135144.

Mehta, R., Kellum, J., Shah, S., Molitoris, B., Ronco,


C., Warnock, D. etal. (2007) Acute kidney injury
network: report of an initiative to improve outcomes
in kidney injury. Crit Care 11: R31.

Lenz, K. (2005) Hepatorenal syndrome is it


hypovolemia, a cardiac disease, or part of gradually
developing multiorgan dysfunction. Hepatology 42:
263265.
Lenz, K., Hrtnagl, H., Druml, W., Reither, H.,
Schmid, R., Schneeweiss, B. etal. (1991) Ornipressin
in the treatment of functional renal failure in
decompensates liver cirrhosis. Gastroenterology 101:
10601067.
LeVeen, H., Christoudias, G., Ip, M., Luft, R.,
Flak, G. and Grosberg, S. (1974) Peritoneo-venous
shunting for ascites. Ann Surg 180: 580591.
Levy, M and Wexler, M. (1987) Hepatic denervation
alters first phase urinary sodium excretion in dogs
with cirrhosis. Am J Physiol 253: F664F671.
Lodhia, N., Kader, M., Mayes, T., Mantry, P.
and Maliakkal, B. (2009) Risk of contrast induced
nephropathy in hospitalized patients with cirrhosis.
World J Gastroenterol 15: 14591464.
Maddukuri, G., Cai, C., Munigala, S., Mohammadi,
F. and Zhang, Z. (2014) Targeting an early and
substantial increase in mean arterial pressure is critical
in the management of type 1 hepatorenal syndrome:
a combined retrospective and pilot study. Dig Dis Sci
59: 471481.
Mahmoodi, K., Sohrabi, B., Ilkhchooyi, F., Malaki,
M., Khaniani, M. and Hemmati, M. (2014). The
efficacy of hydration with normal saline versus
hydration with sodium bicarbonate in the prevention
of contrast-induced nephropathy. Heart Views 15:
3336.
Martin-Llahi, M., Pepin, M., Guevara, M., Diaz, F.,
Torre, A., Monescillo, A. etal. (2008) Terlipressin
and albumin versus albumin in patients with cirrhosis
and hepatorenal syndrome: a randomized study.
Gastroenterology 134: 13521359.
Martinet, O., Reis, E. and Mosimann, F. (2000)
Delayed hemoperitoneum following large-volume
paracentesis in a patient with cirrhosis and ascites. Dig
Dis Sci 45: 357358.
Mathurin, P., Louvert, A., Duhamei, A., Nahon, P.,
Carbonell, N. Buursier, J. etal. (2013) Prednisolone
with vs without pentoxifylline and survival of patients
with severe alcoholic hepatitis. A randomized trial.
JAMA 310: 10331041.

Ming, Z., Smyth, D. and Lautt, W. (2002) Decreases


in portal flow trigger a hepatorenal reflex to inhibit
renal sodium and water excretion in rats: role of
adenosine. Hepatology 35: 167175.
Mitzner, S., Stange, J., Klammt, S., Risler, T.,
Erley, C., Bader, B. etal. (2000) Improvement of
hepatorenal syndrome with extracorporeal albumin
dialysis MARS: Results of a prospective, randomized,
controlled trial. Liver Transplant 6: 277286.
Moore, K. (2013) Acute kidney injury in cirrhosis: A
changing spectrum. Hepatology 57: 435437.
Moore, K. and Aithal, G. (2006) Guidelines on the
management of ascites in cirrhosis. Gut 55(Suppl. 6):
vi112.
Moore, K., Wong, F., Gines, P., Bernardi, M., Ochs,
A. and Salerno, F. (2003) The management of ascites
in cirrhosis: report on the consensus conference of the
International Ascites Club. Hepatology 38: 258266.
Nadim, M., Kellum, J., Davenport, A., Wong, F.,
Davis, C., Pannu, N. etal. (2012) Hepatorenal
syndrome: the 8th international conference of the
acute dialysis initiative (ADQI) group. Crit Care 16:
R23.
Nazar, A., Pereira, G., Guevara, M., Martin-Llahi,
M., Pepin, M., Marinelli, M. etal. (2011) Predictors
of response to terlipressin plus albumin in hepatorenal
syndrome (HRS) type 1: relationship of serum
creatinine to hemodynamics. J Hepatol 55: 315321.
Neri, S., Pulvirent, D., Malaguarnera, M., Cosimo,
B., Bertino, G., Ignaccolo, L. etal. (2008) Terlipressin
and albumin in patients with cirrhosis and type I
hepatorenal syndrome. Dig Dis Sci 53: 830835.
Oettl, K., Birner-Gruenberger, R., Spindelmoeck, W.,
Stueger, H., Dorn, L., Stadlbauer, V. etal. (2013).
Oxidative albumin damage in chronic liver failure. A
relation to albumin binding capacity, liver dysfunction
and survival. J Hepatol 59: 978983.
Ortega, R., Gines, P., Uriz, J., Cardenas, A.,
Calahorra, B., Las Heras, D. etal. (2002) Terlipressin
therapy with and without albumin for patients with
hepatorenal syndrome: Results of a prospective,
nonrandomized controlled study. Hepatology 36:
941948.
Perez-Ayuso, R., Arroyo, V., Planas, R., Gaya,
J., Bory, F., Rimola, A. etal. (1982) Randomized

98 http://tag.sagepub.com

K Lenz, R Buder et al.


comparative study of efficacy of furosemide versus
spironolactone in nonacezotemic cirrhosis with
ascites. Relationship between the diuretic response
and the activity of the reninaldosterone system.
Gastroenterology 84: 961968.
Persson, P., Ehmke, H., Nafz, B. and Kirchheim,
R. (1990) Sympathetic modulation of renal
autoregulation by carotid occlusion in conscious dog.
Am J Physiol 258: F364F370.
Peschl, L. (1987) Klinische und experimentell
Untersuchungen ber die Wirkung von Dopamin
auf die Hmodynamik und Funktion von Niere und
Leber. Wien Klin Wochenschr 86(Suppl.): 133.
Pockros, P. and Reynolds, T. (1986) Rapid diuresis
in patients with ascites from chronic liver disease: the
importance of peripheral edema. Gastroenterology 90:
18271833.
Restuccia, T., Ortega, R., Guevara, M., Gines, P.,
Alessandria, C., Ozdogan, O. etal. (2004) Effects
of treatment of hepatorenal syndrome before
transplantation on posttransplantation outcome. A
case control study. J Hepatol 40: 140146.
Ripoli, C., Groszmann, R., Garcia-Tsao, G., Grace,
N., Burroughs, A., Planas, R. etal. (2007) Hepatic
venous gradient predicts clinical decompensation in
patients with compensated cirrhosis. Gastroenterology
133: 481488.
Romanelli, R., Villa, G., Barletta, G., Vizzuti, F.,
Lanini, F., Arena, U. etal. (2006) Long term albumin
infusion improves survival in patients with cirrhosis
and ascites: an unblinded randomized trial. World J
Gastroenterol 12: 14031407.
Rossle, M., Ochs, A., Gulberg, V., Siegerstetter,
V., Holl, J., Deibert, P. etal. (2000) A comparison
of paracentesis and transjugular intrahepatic
portosystemic shunting in patients with ascites. N Engl
J Med 342: 17011707.
Ruiz-del-Arbrol, L., Nonescillo, A., Arocena,
C., Valer, P., Gines, P., Moreira, V. etal. (2005)
Circulatory function and hepatorenal syndrome in
cirrhosis. Hepatology 42: 439447.
Runyon, B. (2012) Introduction to the revised
American Association for the Study of Liver Diseases
practice guideline management of adult patients with
ascites due to cirrhosis 2012. Hepatology 57: 1651
1653.
Runyon, B., Hoefs, J. and Morgan, T. (1988)
Ascitic fluid analysis in malignancy- related ascites.
Hepatology 8: 11041109.
Ryckwaert, F., Visolvy, A., Fort, A., Murat, B.,
Richard, S. Guillon, G. etal. (2009) Terlipressin, a
provasopressin drug exhibits direct vasoconstrictor
properties: Consequences on heart perfusion and
performance. Crit Care Med 37: 876881.

Salerno, F., Gerbes, A., Gines, P., Wong, F. and


Arroyo, V. (2007) Diagnosis, prevention and
treatment of hepatorenal syndrome in cirrhosis. Gut
56: 13101318.
Salerno, F., Merli, M., Riggio, O., Cazzaniga, M.,
Valeriano, V., Pozzi, M. etal. (2004) Randomized
controlled study of TIPS versus paracentesis plus
albumin in cirrhosis with severe ascites. Hepatology 40:
629635.
Salerno, F., Navickis, R. and Wilkes, M. (2013)
Albumin infusion improves outcomes of patients
with spontaneous bacterial peritonitis: A metanalysis
of randomized trials. Clin Gastroenterol Hepatol 11:
123130.
Santos, J., Planas, R., Pardo, A., Durandez, R.,
Cabre, E., Morllas, R. etal. (2003) Spironolactone
alone or in combination with furosemide in the
treatment of moderate ascites in nonazotemic
cirrhosis. A randomized comparative study of efficacy
and safety. J Hepatol 39: 187192.
Sanyal, A., Boyer, T., Garcia-Tsao, G., Regenstein,
F., Rossaro, L., Appenrodt, B. etal. (2008) A
randomized prospective double-blind placebocontrolled trial of terlipressin for type 1 hepatorenal
syndrome. Gastroenterology 134: 13601368.
Sanyal, A., Freedman, A., Shiffman, M., Purdum, P.,
Luketic, V. and Cheatham, A. (1994) Portosystemic
encephalopathy after transjugular intrahepatic
portosystemic shunt: results of a prospective
controlled study. Hepatology 20: 4655.
Sanyal, A., Genning, C., Reddy, K., Wong, F.,
Kowdley, K., Benner, K. etal. (2003) The North
America study for the treatment of refractory ascites.
Gastroenterology 124: 634641.
Serste, T., Francoz, C., Durand, F., Rautou, P.,
Valla, D., Moreau, R. etal. (2010) Deleterious effects
of betablockers on survival in patients with cirrhosis
and refractory ascites. Hepatology 52: 10171022.
Sharma, P., Kumar, A., Shrama, B. and Sarin, S.
(2008) An open label, pilot, randomized controlled
trial of noradrenaline versus terlipressin in the
treatment of type 1 hepatorenal syndrome and
predictors of response. Am J Gastroenterol 103:
16891697.
Singh, V., Dhungana, S., Singh, B., Vijayverghia,
R., Nain, C., Sharma, N. etal. (2012a) Midodrine
in patients with cirrhosis and refractory ascites: a
randomized pilot study. J Hepatol 56: 348354.
Singh, V., Ghosh, S., Singh, B., Kumar, P., Sharma,
N. and Bhalla, A. (2012b) Noradrenaline vs.
terlipressin in the treatment of hepatorenal syndrome:
a randomized study. J Hepatol 56: 12931298.
Singh, V., Singh, A., Singh, B., Vijayvergiya, R.,
Sharma, N., Ghai, A. etal. (2013) Midodrine and

http://tag.sagepub.com 99

Therapeutic Advances in Gastroenterology 8(2)


clonidine in patients with cirrhosis and refractory
or recurrent ascites: a randomized pilot study. Am J
Gastroenterol 108: 560567.
Skagen, C., Einstein, M., Lucey, M. and Said, A.
(2009) Combination treatment with octreotide,
midodrine, and albumin improves survival in patients
with type 1 and type 2 hepatorenal syndrome. J Clin
Gastroenterol 43: 680685.
Solanki, P., Chawla, A., Garg, R., Gupta, R., Jain, M.
and Sarin, S. (2003) Beneficial effects of terlipressin
in hepatorenal syndrome: a prospective, randomized
placebo-controlled clinical trial. J Gastroenterol Hepatol
18: 152156.
Solis-Herruzo, J., Duran, A., Favela, V., Castellano,
G., Madrid, J., Munoz-Yaguem, M. etal. (1987)
Effects of lumbar sympathetic block on kidney
function in cirrhotic patients with hepatorenal
syndrome. J Hepatol 5: 167173.
Somberg, K., Riegler, J., LaBerge, J., Doherty-Simor,
M., Bachetti, P., Roberts, J. etal. (1995) Hepatic
encephalopathy after transjugular intrahepatic
portosystemic shunts: incidence and risk factors. Am J
Gastroenterol 90: 549555.
Sort, P., Navas, M., Arroyo, V., Aldeguer, X.,
Planas, R., Ruiz-del-Arbol, L. etal. (1999) Effect
of intravenous albumin on renal impairment and
mortality in patients with cirrhosis and spontaneous
bacterial peritonitis. N Engl J Med 341: 403409.
Soulsby, C., Madden, A. and Morgan, M. (1997)
The effect of dietary sodium restriction on energy and
protein intake. Hepatology 26(Suppl. 382A): 1013.

Visit SAGE journals online


http://tag.sagepub.com

SAGE journals

Stadlbauer, V., Wright, G., Banaji, M., Mukhopadhya,


A., Mookejee, R., Moore, K. etal. (2008) Relationship
between activation of the sympathetic nervous system
and renal blood flow autoregulation in cirrhosis.
Gastroenterology 134: 111119.
Trawal, J., Paradis, V., Rautou, P., Francoz,
C., Escolano, S., Salle, M. etal. (2010) The

spectrum of renal lesions in patients with cirrhosis: a


clinicopathological study. Liver Int 30: 725732.
Tzamaloukas, A., Malhotra, D., Rosen, B., Raj,
D., Murata, G. and Shapiro, J. (2013) Principles of
management of severe hyponatremia. J Am Heart
Assoc 2(4): e000240.
Umgelter, A., Reindl, W., Huber, W. and Schmid, R.
(2009) Renal resistive index and renal function before
and after paracentesis in patients with hepatorenal
syndrome and tense ascites. Intensive Care Med 35:
152156.
Umgelter, A., Wagner, K., Reindl, W., Luppa,
P., Geisler, F., Huber, W. etal. (2012) Renal and
circulatory effects of large volume plasma expansion
in patients with hepatorenals syndrome type 1. Ann
Hepatology 11: 232239.
Velez, J. and Nietert, P. (2011) Therapeutic response
to vasoconstrictors in hepatorenal syndrome parallels
increase in mean arterial pressure: a pooled analysis of
clinical trials. Am J Kidney Dis 58: 928938.
Witzke, O., Baumann, M., Patschan, D., Patschan,
S., Mitchell, A., Treichel, U. etal. (2004) Which
patients benefit from hemodialysis therapy in
hepatorenal syndrome? J Gastroenterol Hepatol 19:
13691373.
Wong, F., Massie, D., Hsu, P. and Dudley, F. (1994)
Dose dependent effects of oral misoprostol on renal
function in alcoholic cirrhosis. Gastroenterology 106:
658663.
Wong, F., Nadim, M., Kellum, J., Salerno, F.,
Bellomo, R., Gerbes, A. etal. (2011). Working
party proposal for a revised classification system of
renal dysfunction in patients with cirrhosis. Gut 60:
702709.
Wong, F., Pantea, L. and Sniderman, K. (2004)
Midodrine, octreotide, albumin and TIPS selected
patients with cirrhosis and type 1 hepatorenal
syndrome. Hepatology 40: 5564.

100 http://tag.sagepub.com